SPCS3
gene geneOn this page
Also known as FLJ22649SPC22/23SPC3YLR066WPRO3567
Summary
SPCS3 (signal peptidase complex subunit 3, HGNC:26212) is a protein-coding gene on chromosome 4q34.2, encoding Signal peptidase complex subunit 3 (P61009). Essential component of the signal peptidase complex (SPC) which catalyzes the cleavage of N-terminal signal sequences from nascent proteins as they are translocated into the lumen of the endoplasmic reticulum. It is a common-essential gene (DepMap: required in 95.1% of cancer cell lines).
Involved in obsolete signal peptide processing and viral protein processing. Located in endoplasmic reticulum membrane.
Source: NCBI Gene 60559 — automated summary from GO annotations (Alliance of Genome Resources).
At a glance
- GWAS associations: 9
- Clinical variants (ClinVar): 28 total — 1 pathogenic
- GTEx eGene: eQTL in 26 tissues, sQTL in 1 (q < 0.05)
- Cancer dependency (DepMap): dependent in 95.1% of screened cell lines (common-essential)
- Constraint (gnomAD): pLI 0.84 (intermediate), LOEUF 0.62 (unconstrained)
- MANE Select transcript:
NM_021928
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:26212 |
| Approved symbol | SPCS3 |
| Name | signal peptidase complex subunit 3 |
| Location | 4q34.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | FLJ22649, SPC22/23, SPC3, YLR066W, PRO3567 |
| Ensembl gene | ENSG00000129128 |
| Ensembl biotype | protein_coding |
| OMIM | 618854 |
| Entrez | 60559 |
Gene structure
Transcript identifiers
Ensembl transcripts: 8 — 4 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay
MANE Select: ENST00000503362
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 3
ENST00000503362, ENST00000507001, ENST00000507678, ENST00000513139, ENST00001044112, ENST00001121319, ENST00001121320, ENST00001133466
RefSeq mRNA: 1 — MANE Select: NM_021928
NM_021928
CCDS: CCDS54823
Canonical transcript exons
ENST00000503362 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000886396 | 176328198 | 176332245 |
| ENSE00002065140 | 176319966 | 176320219 |
| ENSE00003524373 | 176327162 | 176327277 |
| ENSE00003530109 | 176322170 | 176322243 |
| ENSE00003600295 | 176324181 | 176324257 |
Expression profiles
Bgee: expression breadth ubiquitous, 288 present calls, max score 97.62.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 65.8625 / max 367.3419, expressed in 1823 samples.
Highest expression (Bgee): corpus epididymis, gingival epithelium, pylorus, bone marrow cell, esophagus squamous epithelium.
Genetic regulation across tissues (GTEx eQTL / sQTL)
SPCS3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 26 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
showing 20 of 27 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Artery Tibial | eqtl | 5.7e-12 | +0.26 | 4:176328530:A:G |
| Cells Cultured fibroblasts | eqtl | 1.5e-10 | +0.19 | 4:176328605:A:G |
| Colon Sigmoid | eqtl | 2.9e-08 | -0.25 | 4:176305155:T:C |
| Muscle Skeletal | eqtl | 4.3e-08 | +0.21 | 4:176334636:TATATACACACAC:T |
| Testis | eqtl | 4.9e-08 | -0.29 | 4:176319985:C:T |
| Brain Nucleus accumbens basal ganglia | eqtl | 5.8e-08 | +0.28 | 4:176334975:G:A |
| Colon Transverse | eqtl | 7.4e-07 | -0.18 | 4:176307656:A:G |
| Esophagus Muscularis | eqtl | 8.6e-07 | +0.24 | 4:176334636:TATATACACACAC:T |
| Artery Aorta | eqtl | 1.3e-06 | +0.19 | 4:176328530:A:G |
| Cells EBV-transformed lymphocytes | eqtl | 9.0e-05 | +0.25 | 4:176335786:C:T |
| Esophagus Mucosa | eqtl | 5.6e-04 | +0.15 | 4:176328530:A:G |
| Brain Caudate basal ganglia | eqtl | 8.5e-04 | +0.21 | 4:176334975:G:A |
| Adipose Subcutaneous | eqtl | 1.1e-03 | +0.14 | 4:176334636:TATATACACACAC:T |
| Breast Mammary Tissue | eqtl | 1.5e-03 | +0.14 | 4:176317701:G:A |
| Adipose Visceral Omentum | eqtl | 2.6e-03 | +0.16 | 4:176328530:A:G |
| Artery Coronary | eqtl | 3.3e-03 | -0.51 | 4:176952700:T:G |
| Thyroid | eqtl | 4.4e-03 | +0.11 | 4:176335786:C:T |
| Esophagus Gastroesophageal Junction | eqtl | 4.9e-03 | +0.25 | 4:176334636:TATATACACACAC:T |
| Brain Spinal cord cervical c-1 | eqtl | 5.8e-03 | -0.26 | 4:176228367:C:T |
| Lung | eqtl | 7.6e-03 | +0.15 | 4:176334636:TATATACACACAC:T |
FANTOM5 promoters
2 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 50700 | 65.3812 | 1823 |
| 50701 | 0.4813 | 215 |
Top tissues by expression
showing 100 of 288 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| corpus epididymis | UBERON:0004359 | 97.62 | gold quality |
| gingival epithelium | UBERON:0001949 | 97.61 | gold quality |
| pylorus | UBERON:0001166 | 97.55 | gold quality |
| bone marrow cell | CL:0002092 | 97.50 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 97.48 | gold quality |
| decidua | UBERON:0002450 | 97.40 | gold quality |
| body of pancreas | UBERON:0001150 | 97.37 | gold quality |
| renal glomerulus | UBERON:0000074 | 97.15 | gold quality |
| gingiva | UBERON:0001828 | 97.11 | gold quality |
| germinal epithelium of ovary | UBERON:0001304 | 97.10 | gold quality |
| monocyte | CL:0000576 | 96.95 | gold quality |
| mononuclear cell | CL:0000842 | 96.95 | gold quality |
| metanephric glomerulus | UBERON:0004736 | 96.94 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 96.87 | gold quality |
| squamous epithelium | UBERON:0006914 | 96.83 | gold quality |
| leukocyte | CL:0000738 | 96.81 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 96.72 | gold quality |
| middle temporal gyrus | UBERON:0002771 | 96.69 | gold quality |
| cardia of stomach | UBERON:0001162 | 96.61 | gold quality |
| bone marrow | UBERON:0002371 | 96.61 | gold quality |
| endometrium | UBERON:0001295 | 96.60 | gold quality |
| parotid gland | UBERON:0001831 | 96.50 | gold quality |
| Brodmann (1909) area 23 | UBERON:0013554 | 96.49 | gold quality |
| caput epididymis | UBERON:0004358 | 96.48 | gold quality |
| upper leg skin | UBERON:0004262 | 96.46 | gold quality |
| dorsal motor nucleus of vagus nerve | UBERON:0002870 | 96.40 | gold quality |
| seminal vesicle | UBERON:0000998 | 96.37 | gold quality |
| trachea | UBERON:0003126 | 96.33 | gold quality |
| buccal mucosa cell | CL:0002336 | 96.29 | gold quality |
| tonsil | UBERON:0002372 | 96.26 | gold quality |
| pancreas | UBERON:0001264 | 96.19 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 96.17 | gold quality |
| heart right ventricle | UBERON:0002080 | 96.17 | gold quality |
| endothelial cell | CL:0000115 | 96.14 | gold quality |
| visceral pleura | UBERON:0002401 | 96.14 | gold quality |
| nephron tubule | UBERON:0001231 | 96.12 | gold quality |
| vermiform appendix | UBERON:0001154 | 96.08 | gold quality |
| inferior olivary complex | UBERON:0002127 | 96.04 | gold quality |
| caecum | UBERON:0001153 | 96.03 | gold quality |
| superficial temporal artery | UBERON:0001614 | 96.03 | gold quality |
| placenta | UBERON:0001987 | 95.99 | gold quality |
| periodontal ligament | UBERON:0008266 | 95.97 | gold quality |
| oviduct epithelium | UBERON:0004804 | 95.96 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 95.94 | gold quality |
| lymph node | UBERON:0000029 | 95.88 | gold quality |
| cauda epididymis | UBERON:0004360 | 95.88 | gold quality |
| superior surface of tongue | UBERON:0007371 | 95.86 | gold quality |
| pleura | UBERON:0000977 | 95.82 | gold quality |
| lower lobe of lung | UBERON:0008949 | 95.79 | gold quality |
| cranial nerve II | UBERON:0000941 | 95.64 | gold quality |
| parietal pleura | UBERON:0002400 | 95.62 | gold quality |
| palpebral conjunctiva | UBERON:0001812 | 95.55 | gold quality |
| amniotic fluid | UBERON:0000173 | 95.42 | gold quality |
| oral cavity | UBERON:0000167 | 95.41 | gold quality |
| mammalian vulva | UBERON:0000997 | 95.39 | gold quality |
| pericardium | UBERON:0002407 | 95.36 | gold quality |
| epithelium of nasopharynx | UBERON:0001951 | 95.27 | gold quality |
| stromal cell of endometrium | CL:0002255 | 95.22 | gold quality |
| skin of hip | UBERON:0001554 | 95.20 | gold quality |
| rectum | UBERON:0001052 | 95.03 | gold quality |
| epithelial cell of pancreas | CL:0000083 | 94.96 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 94.91 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 94.88 | gold quality |
| penis | UBERON:0000989 | 94.85 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 94.84 | gold quality |
| lung | UBERON:0002048 | 94.70 | gold quality |
| islet of Langerhans | UBERON:0000006 | 94.67 | gold quality |
| colonic mucosa | UBERON:0000317 | 94.67 | gold quality |
| uterus | UBERON:0000995 | 94.67 | gold quality |
| epithelium of mammary gland | UBERON:0003244 | 94.64 | gold quality |
| blood vessel layer | UBERON:0004797 | 94.62 | gold quality |
| mucosa of urinary bladder | UBERON:0001259 | 94.58 | gold quality |
| trigeminal ganglion | UBERON:0001675 | 94.58 | gold quality |
| tibia | UBERON:0000979 | 94.57 | gold quality |
| nipple | UBERON:0002030 | 94.57 | gold quality |
| saphenous vein | UBERON:0007318 | 94.57 | gold quality |
| choroid plexus epithelium | UBERON:0003911 | 94.52 | gold quality |
| urinary bladder | UBERON:0001255 | 94.49 | gold quality |
| duodenum | UBERON:0002114 | 94.37 | gold quality |
| tongue | UBERON:0001723 | 94.30 | gold quality |
| jejunal mucosa | UBERON:0000399 | 94.28 | gold quality |
| mammary duct | UBERON:0001765 | 94.24 | gold quality |
| renal medulla | UBERON:0000362 | 94.20 | gold quality |
| dorsal root ganglion | UBERON:0000044 | 94.18 | gold quality |
| fallopian tube | UBERON:0003889 | 94.18 | gold quality |
| mammary gland | UBERON:0001911 | 94.15 | gold quality |
| thoracic mammary gland | UBERON:0005200 | 94.12 | gold quality |
| kidney epithelium | UBERON:0004819 | 94.11 | gold quality |
| adrenal tissue | UBERON:0018303 | 94.08 | gold quality |
| right lung | UBERON:0002167 | 94.03 | gold quality |
| nasal cavity mucosa | UBERON:0001826 | 94.00 | gold quality |
| entorhinal cortex | UBERON:0002728 | 93.95 | gold quality |
| metanephros | UBERON:0000081 | 93.89 | gold quality |
| mucosa of paranasal sinus | UBERON:0005030 | 93.80 | gold quality |
| gall bladder | UBERON:0002110 | 93.77 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 93.70 | gold quality |
| jejunum | UBERON:0002115 | 93.68 | gold quality |
| Brodmann (1909) area 46 | UBERON:0006483 | 93.65 | gold quality |
| layer of synovial tissue | UBERON:0007616 | 93.63 | gold quality |
| upper lobe of lung | UBERON:0008948 | 93.63 | gold quality |
Single-cell (SCXA)
Detected in 13 experiment(s), a significant marker in 12.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-CURD-88 | yes | 105.24 |
| E-MTAB-9467 | yes | 67.08 |
| E-HCAD-1 | yes | 63.15 |
| E-HCAD-4 | yes | 60.60 |
| E-CURD-46 | yes | 54.14 |
| E-CURD-122 | yes | 49.79 |
| E-MTAB-8410 | yes | 39.63 |
| E-HCAD-11 | yes | 23.09 |
| E-HCAD-9 | yes | 19.59 |
| E-MTAB-10553 | yes | 10.70 |
| E-HCAD-13 | yes | 7.01 |
| E-CURD-112 | no | 3.03 |
| E-ANND-3 | no | 0.00 |
HPA expression
RNA tissue specificity: Low tissue specificity
showing 60 of 76 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Salivary gland | tissue | 93.4 | low |
| Bone marrow | tissue | 64.3 | low |
| Thyroid gland | tissue | 58.2 | medium |
| Appendix | tissue | 47.8 | medium |
| Pancreas | tissue | 47.2 | medium |
| Lymph node | tissue | 47.1 | |
| Stomach 1 | tissue | 46.1 | medium |
| Tonsil | tissue | 45.2 | low |
| Epididymis | tissue | 44.8 | medium |
| Cervix | tissue | 43.8 | medium |
| Spleen | tissue | 43.8 | not detected |
| Placenta | tissue | 42.8 | high |
| Liver | tissue | 40.7 | low |
| Urinary bladder | tissue | 38.4 | low |
| Endometrium 1 | tissue | 36.1 | medium |
| Heart muscle | tissue | 35.2 | low |
| Rectum | tissue | 35.2 | medium |
| Colon | tissue | 34.7 | medium |
| Small intestine | tissue | 34.7 | high |
| Lung | tissue | 34.1 | medium |
| Breast | tissue | 33.7 | not detected |
| Thalamus | tissue | 32.8 | |
| Choroid plexus | tissue | 32.7 | |
| Smooth muscle | tissue | 32.5 | low |
| Duodenum | tissue | 32.5 | medium |
| Thymus | tissue | 32.5 | |
| Superior colliculi | tissue | 31.9 | |
| Kidney | tissue | 31.8 | medium |
| Adipose tissue | tissue | 30.9 | not detected |
| Prostate | tissue | 30.8 | low |
| Pons | tissue | 30.2 | |
| Postcentral gyrus | tissue | 30.2 | |
| Locus coeruleus | tissue | 30.1 | |
| Gallbladder | tissue | 30.0 | medium |
| Nucleus accumbens | tissue | 29.7 | |
| Parathyroid gland | tissue | 29.4 | |
| Pituitary gland | tissue | 28.5 | |
| Seminal vesicle | tissue | 28.2 | low |
| Midbrain | tissue | 27.8 | |
| Hypothalamus | tissue | 26.2 | |
| Hippocampus | tissue | 26.1 | low |
| Olfactory bulb | tissue | 26.1 | |
| Cerebellum | tissue | 25.9 | not detected |
| Skin 1 | tissue | 25.4 | low |
| Cerebral cortex | tissue | 25.3 | low |
| Substantia nigra | tissue | 25.3 | |
| Somatosensory cortex | tissue | 25.3 | |
| Hippocampal formation | tissue | 25.1 | |
| Tongue | tissue | 24.6 | |
| Vagina | tissue | 24.1 | not detected |
| Entorhinal cortex | tissue | 23.9 | |
| Septum | tissue | 23.9 | |
| Motor cortex | tissue | 23.6 | |
| Esophagus | tissue | 23.4 | not detected |
| Adrenal gland | tissue | 23.3 | medium |
| Prefrontal cortex | tissue | 23.2 | |
| Fallopian tube | tissue | 23.2 | medium |
| Occipital cortex | tissue | 23.0 | |
| Temporal cortex | tissue | 22.6 | |
| Cingulate cortex | tissue | 22.5 |
Brain sub-regions (HPA Brain Atlas): detected in 191; highest nTPM — Ventral tegmental area (51.2), Lateral funiculus (white matter) (45.8), Dorsal funiculus (white matter) (42.8), Anterior funiculus (white matter) (41.5), Cervical spinal cord, ventral horn (39.8).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting SPCS3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 199 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-3163 | 100.00 | 77.23 | 8605 |
| HSA-MIR-3613-3P | 100.00 | 76.36 | 7965 |
| HSA-MIR-3646 | 100.00 | 73.56 | 5283 |
| HSA-MIR-30A-5P | 100.00 | 76.31 | 3233 |
| HSA-MIR-30B-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30C-5P | 100.00 | 76.29 | 3248 |
| HSA-MIR-30D-5P | 100.00 | 76.32 | 3233 |
| HSA-MIR-30E-5P | 100.00 | 76.32 | 3242 |
| HSA-MIR-126-5P | 100.00 | 72.71 | 3180 |
| HSA-MIR-340-5P | 100.00 | 72.50 | 4437 |
| HSA-MIR-8485 | 100.00 | 77.57 | 4731 |
| HSA-MIR-4682 | 100.00 | 68.89 | 1258 |
| HSA-MIR-3662 | 99.99 | 73.82 | 5684 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-186-5P | 99.99 | 70.83 | 3707 |
| HSA-MIR-548C-3P | 99.99 | 74.01 | 7587 |
| HSA-MIR-6077 | 99.99 | 68.04 | 2299 |
| HSA-MIR-520D-5P | 99.98 | 73.34 | 4883 |
| HSA-MIR-524-5P | 99.98 | 73.43 | 4882 |
| HSA-MIR-12136 | 99.98 | 72.81 | 5713 |
| HSA-MIR-4650-5P | 99.98 | 64.69 | 999 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-1250-3P | 99.96 | 70.04 | 4038 |
| HSA-MIR-3605-5P | 99.96 | 67.12 | 932 |
| HSA-MIR-551B-5P | 99.96 | 71.28 | 3493 |
| HSA-MIR-4725-3P | 99.96 | 69.53 | 2520 |
| HSA-MIR-6780B-5P | 99.96 | 69.60 | 2562 |
| HSA-MIR-5688 | 99.96 | 73.23 | 4504 |
| HSA-MIR-495-3P | 99.96 | 72.81 | 4197 |
| HSA-MIR-559 | 99.95 | 72.28 | 3609 |
Functional genomics
gnomAD constraint: pLI 0.838, LOEUF 0.623, missense Z 1.12 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000503362 — one region, missense o/e 0.64.
DepMap (CRISPR cell-line fitness): dependent in 95.1% of screened cell lines, common-essential.
Most-dependent cell lines (DepMap gene-effect, lower = stronger; ≤ −0.5 shown): KMS-20 (-2.035), SNU-668 (-1.925), LOU-NH91 (-1.866), KALS-1 (-1.835), VCaP (-1.776), HCC1419 (-1.734), MHH-ES-1 (-1.714), PSN1 (-1.702), HCC1428 (-1.68), SNU-626 (-1.676), UACC-62 (-1.673), COR-L279 (-1.605), U-178 (-1.598), Calu-6 (-1.593), G-402 (-1.574).
Cross-species orthologs
6 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | spcs3 | ENSDARG00000089976 |
| mus_musculus | Arxes2 | ENSMUSG00000048040 |
| mus_musculus | Arxes1 | ENSMUSG00000048355 |
| rattus_norvegicus | ENSRNOG00000078288 | |
| drosophila_melanogaster | Spase22-23 | FBGN0039172 |
| caenorhabditis_elegans | WBGENE00019679 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Canis lupus familiaris | P61008 | 100.0% | Diamond |
| Bos taurus | Q3SZU5 | 100.0% | Diamond |
| Gallus gallus | P28687 | 90.0% | Diamond |
| Arabidopsis thaliana | Q53YF3 | 88.0% | Diamond |
| Caenorhabditis briggsae | Q60MW2 | 85.0% | Diamond |
| Saccharomyces cerevisiae S288C | Q12133 | 49.4% | Diamond |
| Debaryomyces hansenii CBS767 | Q6BPD6 | 49.4% | Diamond |
| Yarrowia lipolytica CLIB122 | Q6C4R5 | 47.0% | Diamond |
| Oryza sativa Japonica Group | Q9LGB4 | 46.8% | Diamond |
| Kluyveromyces lactis NRRL Y-1140 | Q6CRY8 | 41.7% | Diamond |
| Dictyostelium discoideum | B0G180 | 40.9% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| HAFML | ncRNA | 105377555 |
| LINC02509 | ncRNA | 105377556 |
| SPCS3-AS1 | ncRNA | 116435303 |
| VEGFC | protein-coding | 7424 |
| SPATA4 | protein-coding | 132851 |
| ASB5 | protein-coding | 140458 |
| WDR17 | protein-coding | 116966 |
Protein
Protein identifiers
Signal peptidase complex subunit 3 — P61009 (reviewed: P61009)
Alternative names: Microsomal signal peptidase 22/23 kDa subunit
All UniProt accessions (1): P61009
UniProt curated annotations — full annotation on UniProt →
Function. Essential component of the signal peptidase complex (SPC) which catalyzes the cleavage of N-terminal signal sequences from nascent proteins as they are translocated into the lumen of the endoplasmic reticulum. Essential for the SPC catalytic activity, possibly by stabilizing and positioning the active center of the complex close to the lumenal surface. (Microbial infection) Plays an important role in virion production of flaviviruses such as West Nile virus, Japanese enchephalitis virus, Dengue virus type 2 and Yellow Fever virus.
Subunit / interactions. Component of the signal peptidase complex paralog A (SPC-A) composed of a catalytic subunit SEC11A and three accessory subunits SPCS1, SPCS2 and SPCS3. Component of the signal peptidase complex paralog C (SPC-C) composed of a catalytic subunit SEC11C and three accessory subunits SPCS1, SPCS2 and SPCS3. Within the complex, interacts with SEC11A or SEC11C and SPCS1. The complex induces a local thinning of the ER membrane which is used to measure the length of the signal peptide (SP) h-region of protein substrates. This ensures the selectivity of the complex towards h-regions shorter than 18-20 amino acids.
Subcellular location. Endoplasmic reticulum membrane.
Similarity. Belongs to the SPCS3 family.
RefSeq proteins (1): NP_068747* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR007653 | SPC3 | Family |
Pfam: PF04573
UniProt features (6 total): topological domain 2, chain 1, transmembrane region 1, glycosylation site 1, sequence conflict 1
Structure
Experimental structures (PDB)
4 structures by resolution:
| PDB | Title | Method | Resolution (Å) |
|---|---|---|---|
| 9RJB | Human Signal Peptidase in complex with artificial Signal Peptide L11 | ELECTRON MICROSCOPY | 2.6 |
| 9RJC | Apo Structure of the Human Signal Peptidase | ELECTRON MICROSCOPY | 4.2 |
| 7P2P | Human Signal Peptidase Complex Paralog A (SPC-A) | ELECTRON MICROSCOPY | 4.9 |
| 7P2Q | Human Signal Peptidase Complex Paralog C (SPC-C) | ELECTRON MICROSCOPY | 4.9 |
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-P61009-F1 | 91.72 | 0.83 |
Human Protein Atlas
Protein class: Metabolic proteins, Predicted intracellular proteins, Essential proteins
Protein evidence: Evidence at protein level
Antibody reliability (HPA): IH approved
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (1)
| Type | Positions |
|---|---|
| N-linked (glcnac…) asparagine | 141 |
Function
Pathways and Gene Ontology
Reactome pathways
4 curated (TAS) of 23; 7 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
23 pathways:
| ID | Pathway | Evidence |
|---|---|---|
| R-HSA-9918432 | Maturation of DENV proteins ⚕ | curated |
| R-HSA-9828806 | Maturation of hRSV A proteins ⚕ | curated |
| R-HSA-9768727 | Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | curated |
| R-HSA-422085 | Synthesis, secretion, and deacylation of Ghrelin | curated |
| R-HSA-1643685 | Disease ⚕ | — |
| R-HSA-5663205 | Infectious disease ⚕ | — |
| R-HSA-9820952 | Respiratory Syncytial Virus Infection Pathway ⚕ | — |
| R-HSA-9820965 | Respiratory syncytial virus (RSV) genome replication, transcription and translation ⚕ | — |
| R-HSA-9824446 | Viral Infection Pathways ⚕ | — |
| R-HSA-418990 | Adherens junctions interactions | — |
| R-HSA-446728 | Cell junction organization | — |
| R-HSA-1500931 | Cell-Cell communication | — |
| R-HSA-421270 | Cell-cell junction organization | — |
| R-HSA-400508 | Incretin synthesis, secretion, and inactivation | — |
| R-HSA-392499 | Metabolism of proteins | — |
| R-HSA-2980736 | Peptide hormone metabolism | — |
| R-HSA-9764265 | Regulation of CDH1 Expression and Function | — |
| R-HSA-9764274 | Regulation of Expression and Function of Type I Classical Cadherins | — |
| R-HSA-9759476 | Regulation of Homotypic Cell-Cell Adhesion | — |
| R-HSA-1799339 | SRP-dependent cotranslational protein targeting to membrane | electronic |
| R-HSA-381771 | Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | electronic |
| R-HSA-400511 | Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP) | electronic |
| R-HSA-72766 | Translation | — |
MSigDB gene sets: 184 (showing top):
RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_PROTEIN_TARGETING, chr4q34, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ENDOPLASMIC_RETICULUM, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_ORGANELLE, REACTOME_ADHERENS_JUNCTIONS_INTERACTIONS, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_PROTEIN_MATURATION, MORI_PLASMA_CELL_UP, WANG_RESPONSE_TO_FORSKOLIN_UP, IVANOVA_HEMATOPOIESIS_INTERMEDIATE_PROGENITOR, WANG_RESPONSE_TO_ANDROGEN_UP, WANG_PROSTATE_CANCER_ANDROGEN_INDEPENDENT, GOBP_SIGNAL_PEPTIDE_PROCESSING
GO Biological Process (4): proteolysis (GO:0006508), viral protein processing (GO:0019082), protein targeting to ER (GO:0045047), protein processing (GO:0016485)
GO Molecular Function (1): protein binding (GO:0005515)
GO Cellular Component (4): endoplasmic reticulum (GO:0005783), signal peptidase complex (GO:0005787), endoplasmic reticulum membrane (GO:0005789), membrane (GO:0016020)
Reactome top-level categories
14 top-level categories:
| Category | Pathways |
|---|---|
| Incretin synthesis, secretion, and inactivation | 2 |
| Peptide hormone metabolism | 2 |
| Metabolism of proteins | 2 |
| Translation | 1 |
| Regulation of CDH1 Expression and Function | 1 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | 1 |
| Dengue Virus Genome Translation and Replication | 1 |
| Cell-cell junction organization | 1 |
| Cell junction organization | 1 |
| Cell-Cell communication | 1 |
| Disease | 1 |
| Adherens junctions interactions | 1 |
| Regulation of Expression and Function of Type I Classical Cadherins | 1 |
| Regulation of Homotypic Cell-Cell Adhesion | 1 |
GO top-level categories
19 GO namespaces:
| Category | Terms |
|---|---|
| protein metabolic process | 1 |
| viral process | 1 |
| viral gene expression | 1 |
| protein targeting | 1 |
| establishment of protein localization to endoplasmic reticulum | 1 |
| proteolysis | 1 |
| protein maturation | 1 |
| binding | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| endoplasmic reticulum membrane | 1 |
| membrane protein complex | 1 |
| endoplasmic reticulum protein-containing complex | 1 |
| serine-type endopeptidase complex | 1 |
| organelle membrane | 1 |
| nuclear outer membrane-endoplasmic reticulum membrane network | 1 |
| endoplasmic reticulum subcompartment | 1 |
| cellular anatomical structure | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 4 of 10 annotations. The rest are phylogenetic / computational / electronic (IEA).
4 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| proteolysis | BP | direct assay |
| viral protein processing | BP | mutant phenotype |
| endoplasmic reticulum | CC | direct assay |
| endoplasmic reticulum membrane | CC | direct assay |
Protein interactions and networks
IntAct
Human interaction partners of SPCS3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
7 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| SEC11C | association | 0.820 | 4 |
| SEC11A | association | 0.770 | 5 |
| ATXN1 | physical association | 0.670 | 3 |
| HTT | physical association | 0.560 | 6 |
| ENTPD6 | association | 0.530 | 2 |
| UFD1 | physical association | 0.400 | 1 |
| XRCC3 | association | 0.350 | 1 |
BioGRID (170 interactions; top human partners by supporting records): SEC11C (Affinity Capture-MS; 3 records), SPCS2 (Affinity Capture-MS; 3 records), CANX (Proximity Label-MS; 2 records), SEC11A (Affinity Capture-MS; 2 records), SLC22A14 (Cross-Linking-MS (XL-MS); 2 records), ABCB6 (Affinity Capture-MS), AMBRA1 (Proximity Label-MS), ANKRD46 (Affinity Capture-MS), AREL1 (Proximity Label-MS), ATXN1 (Affinity Capture-MS), C16orf58 (Affinity Capture-MS), C9orf72 (Affinity Capture-MS), CA9 (Proximity Label-MS), CALR3 (Proximity Label-MS), CDC123 (Affinity Capture-MS)
SIGNOR signaling
2 signaling interactions:
| A | Effect | B | Mechanism |
|---|---|---|---|
| SPCS3 | “form complex” | “Signal peptidase complex, SEC11C variant” | binding |
| SPCS3 | “form complex” | “Signal peptidase complex, SEC11A variant” | binding |
Disease & clinical
Genetic variants
Variant evidence for SPCS3: 28 ClinVar records (1 pathogenic / likely pathogenic); 9 GWAS associations. Per-variant detail is on Sugi Variant.
ClinVar
28 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 14 |
| Likely benign | 0 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (1)
Showing all 1 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.
| Variant ID | HGVS | Classification | Review | Submitters |
|---|---|---|---|---|
| 983279 | GRCh37/hg19 4q32.3-35.1(chr4:169108358-184425536)x1 | Pathogenic | no assertion criteria provided | 1 |
Per-variant reference — Sugi Variant
Explore SPCS3’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 29 predictions of 377):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| 4:176320182 | donor_gain | 1.0000 | |
| 4:176327232 | donor_gain | 1.0000 | |
| 4:176327278–176327279 | donor_loss | 1.0000 | 6 |
| 4:176328302 | donor_gain | 1.0000 | |
| 4:176328324 | donor_gain | 1.0000 | |
| 4:176320220–176320221 | donor_loss | 0.9900 | 5 |
| 4:176327160–176327161 | acceptor_loss | 0.9900 | 6 |
| 4:176328196–176328197 | acceptor_loss | 0.9900 | 6 |
| 4:176320221 | donor_loss | 0.9800 | |
| 4:176328195 | acceptor_loss | 0.9800 |
AlphaMissense
547 missense substitutions predicted likely pathogenic (of 1,171 scored), across 134 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D107 | 8 | 0.993 | 0.998 |
| D131 | 8 | 0.983 | 0.993 |
| D62 | 8 | 0.977 | 0.993 |
| N81 | 8 | 0.977 | 0.998 |
| F86 | 8 | 0.970 | 0.999 |
| D53 | 8 | 0.920 | 0.982 |
| D132 | 8 | 0.908 | 0.964 |
| F129 | 8 | 0.883 | 0.991 |
| F170 | 8 | 0.879 | 0.984 |
| N149 | 8 | 0.869 | 0.990 |
| W80 | 7 | 0.985 | 0.998 |
| W106 | 7 | 0.982 | 0.998 |
| F78 | 7 | 0.955 | 0.985 |
| W148 | 7 | 0.951 | 0.998 |
| F130 | 7 | 0.942 | 0.976 |
| F54 | 7 | 0.936 | 0.985 |
| D79 | 7 | 0.935 | 0.968 |
| N101 | 7 | 0.927 | 0.992 |
| F14 | 7 | 0.920 | 0.976 |
| N9 | 7 | 0.909 | 0.992 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
1 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Kidney Renal Clear Cell Carcinoma (TCGA) | favorable | 0.000575 |
Disease associations
OMIM: gene MIM:618854 | disease phenotypes:
GWAS associations
9 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST003989_18 | Chin dimples | 3e-15 |
| GCST007354_11 | Intracranial aneurysm | 6e-13 |
| GCST005989_11 | Serum total protein levels | 4e-9 |
| GCST010796_3996 | Electrocardiogram morphology (amplitude at temporal datapoints) | 5e-9 |
| GCST005988_4 | Serum albumin levels | 6e-9 |
| GCST010796_3993 | Electrocardiogram morphology (amplitude at temporal datapoints) | 7e-9 |
| GCST010796_3994 | Electrocardiogram morphology (amplitude at temporal datapoints) | 2e-8 |
| GCST010796_3995 | Electrocardiogram morphology (amplitude at temporal datapoints) | 4e-8 |
| GCST004659_1 | Left ventricular mass | 1e-7 |
EFO canonical traits (from GWAS)
2 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0008205 | left ventricular structural measurement |
| EFO:0004327 | electrocardiography |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL6066491 (SINGLE PROTEIN)
PharmGKB: 1 entry (CPIC guideline: no)
Binding affinities (BindingDB)
1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.
| Ligand | Measure | Value |
|---|---|---|
| CHEMBL5653589 | KD | 1440 nM |
CTD chemical–gene interactions
45 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Cyclosporine | increases expression | 4 |
| Valproic Acid | affects expression, increases expression | 3 |
| Phenylmercuric Acetate | affects cotreatment, increases expression | 2 |
| Tobacco Smoke Pollution | increases expression | 2 |
| Tunicamycin | increases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| methylmercuric chloride | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| bisphenol A | increases expression | 1 |
| pyrogallol 1,3-dimethyl ether | affects cotreatment, decreases expression | 1 |
| beta-lapachone | increases expression | 1 |
| sodium arsenite | increases expression | 1 |
| cobaltous chloride | decreases expression | 1 |
| manganese chloride | increases abundance, increases expression | 1 |
| potassium chromate(VI) | affects cotreatment, decreases expression | 1 |
| cupric chloride | increases expression | 1 |
| epigallocatechin gallate | affects cotreatment, decreases expression | 1 |
| perfluorooctane sulfonic acid | decreases expression | 1 |
| CGP 52608 | affects binding, increases reaction | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| ICG 001 | decreases expression | 1 |
| abrine | decreases expression | 1 |
| dorsomorphin | affects cotreatment, increases expression | 1 |
| eprenetapopt | affects reaction, affects expression | 1 |
| bisphenol S | increases expression | 1 |
| bisphenol AF | increases expression | 1 |
| Benzo(a)pyrene | increases expression | 1 |
| Cisplatin | decreases expression | 1 |
| Colforsin | increases expression | 1 |
| Furaldehyde | affects cotreatment, increases expression | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5652513 | Binding | Binding affinity to human SPCS3 incubated for 45 mins by Kinobead based pull down assay | NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — *ChemMedChem* |
Cellosaurus cell lines
1 cell lines: 1 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_B2H5 | Abcam HeLa SPCS3 KO | Cancer cell line | Female |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Predicted chemistry — Sugi Predict
The predicted patent-compound landscape for SPCS3 across ~30M SureChEMBL compounds — explore on Sugi Predict.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): brain aneurysm